A detailed history of Lindbrook Capital, LLC transactions in Merus N.V. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 76 shares of MRUS stock, worth $3,774. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76
Previous 120 36.67%
Holding current value
$3,774
Previous $7,000 57.14%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$47.19 - $58.84 $2,076 - $2,588
-44 Reduced 36.67%
76 $3,000
Q2 2024

Jul 31, 2024

BUY
$39.81 - $60.2 $1,751 - $2,648
44 Added 57.89%
120 $7,000
Q4 2023

Jan 31, 2024

SELL
$20.06 - $28.66 $1,103 - $1,576
-55 Reduced 41.98%
76 $2,000
Q2 2023

Jul 28, 2023

SELL
$18.33 - $27.18 $971 - $1,440
-53 Reduced 28.8%
131 $3,000
Q1 2023

Apr 26, 2023

BUY
$14.25 - $20.5 $1,695 - $2,439
119 Added 183.08%
184 $3,000
Q4 2022

Jan 24, 2023

BUY
$12.8 - $23.66 $832 - $1,537
65 New
65 $0

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.